Evidence map›Paper›PMID 41256135›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

Sehrish Kanwal, Natalie Brajanovski, Jiajun Zhan, Joanna Chan, Richard Rebello, Oliver Hofmann, Sean Grimmond, Luc Furic, Ross D Hannan, Grant McArthur and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sehrish KanwalUniversity of Melbourne, Melbourne, Victoria, Australia.
Natalie BrajanovskiCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jiajun ZhanUniversity of Melbourne, Melbourne, Victoria, Australia.
Joanna ChanDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Richard RebelloUniversity of Melbourne, Melbourne, Victoria, Australia.
Oliver HofmannUniversity of Melbourne, Melbourne, Victoria, Australia.
Sean GrimmondUniversity of Melbourne, Melbourne, Victoria, Australia.
Luc FuricCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-1893-9812
Ross D HannanSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Grant McArthurUniversity of Melbourne, Melbourne, Victoria, Australia.
Gretchen PoortingaSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Simon HarrisonSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Elaine SanijCancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Amit KhotSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Shahneen SandhuUniversity of Melbourne, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Replying to GCC Koh et al., Nature Genetics (www.nature.com/articles/s41588-023-01602-9) and the comments by Simon Boulton in Nature Genetics (www.nature.com/articles/s41588-023-01611-8). The drug CX-5461 [Pidnarulex] is an inhibitor of RNA polymerase I and topoisomerase II and a DNA G-quadruplex stabilizer. Koh et al. recently reported that CX-5461 induces extensive, non-selective collateral mutagenesis

Identifiers

PMID41256135
PMCPMC12622090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.